Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · IEX Real-Time Price · USD
32.68
+1.25 (3.98%)
May 1, 2024, 3:44 PM EDT - Market open
Tarsus Pharmaceuticals Revenue
In the year 2023, Tarsus Pharmaceuticals had annual revenue of $17.45M, a decrease of -32.42%. Revenue in the quarter ending December 31, 2023 was $13.08M with 30.76% year-over-year growth.
Revenue (ttm)
$17.45M
Revenue Growth
-32.42%
P/S Ratio
67.68
Revenue / Employee
$71,504
Employees
244
Market Cap
1.23B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
Dec 31, 2021 | 57.03M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pacira BioSciences | 674.98M |
Collegium Pharmaceutical | 566.77M |
Ironwood Pharmaceuticals | 442.74M |
Phreesia | 356.30M |
Xencor | 168.34M |
Deciphera Pharmaceuticals | 163.36M |
4D Molecular Therapeutics | 20.72M |
Spyre Therapeutics | 886.00K |
TARS News
- 8 days ago - Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon - GlobeNewsWire
- 2 months ago - Tarsus to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis - GlobeNewsWire
- 2 months ago - Tarsus Announces Pricing of $100.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Tarsus Announces Proposed $100.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements - GlobeNewsWire
- 2 months ago - Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease - GlobeNewsWire
- 2 months ago - Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 - GlobeNewsWire